Scythian Biosciences

No. 386: Hofstra in the minority, septuagenarians in bed and Gilbert in the weeds, again (plus: The Dude abides)

  Wednesday welcome: You’ve reached the midpoint of another exciting week of inventions, investments and bold business development. Well done, intrepid reader! It’s March 6 out there, and before we dive in, welcome new newsletter subscribers Lily, Brian, Samantha, Caleb, Brandon, Frank, Alyssa, Ellen, Javier, Melissa, Martez and Joshua. Please make sure your snacks are peanut-free, and enjoy the show. Sometimes there’s a man: Our new friends join us on a special day for the…


Concussion-focused Scythian sets market debut

By GREGORY ZELLER // Scythian Biosciences Corp. is going public. The New York City/Toronto-based biotech, led by Great Neck investment banker Jonathan Gilbert on its quest to develop the world’s first pharmaceutical treatment for concussions, will begin trading Aug. 8 on the TSX Venture Exchange, one of Canada’s major stock markets. Projected to open at $8 (Canadian) per share, Scythian Biosciences (ticker symbol “SCYB”) will float upwards of 2.5 million shares – about half of…


Feinstein, Hofstra concussion study exposes a nerve

By GREGORY ZELLER // With concussions and other traumatic brain injuries continuing to make headlines on and off the playing field, Long Island researchers may be closing in on a unique treatment method. Scientists at the Feinstein Institute for Medical Research and the Hofstra Northwell School of Medicine have published the results of a nerve-stimulation study with broad-ranging implications for many neurological conditions, including severe TBIs. Published online by the international science journal Nature, the…


Financing set, cannabinoid-concussion study aims high

By GREGORY ZELLER // And now, onto the science. Canadian mining exploration company Kitrinor Metals Inc. and Scythian Biosciences Inc., a Calgary-based biotech owned by Great Neck investment banker Jonathan Gilbert, have announced a pair of deals that complete first-round financing for Scythian, which is exploring cannabinoid-based treatments for concussions. The new deals add on to the $13.08 million (Canadian) in brokered financing, led by Ontario-based Clarus Securities Inc., already raised by Scythian Biosciences, which…


Stock deal locks funds for Scythian marijuana study

By GREGORY ZELLER // A Canadian R&D firm with Long Island roots has locked up the first tranche of a strategic investment that will fund a major study involving concussions and medical marijuana. Scythian Biosciences Inc. and Canadian mining exploration company Kitrinor Metals Inc. on Tuesday announced a “brokered private placement” that gives 32.7 million common shares of Calgary-based Scythian, owned by Great Neck investment banker Jonathan Gilbert, to an investment team including lead agent…


Scythian, U of M concussion study hits the jack-pot

By GREGORY ZELLER // A Calgary-based R&D firm with strong Long Island ties has swung an eight-figure financing deal, lighting up a major study pitting cannabinoids against concussions. Scythian Biosciences Inc. – owned by owned by Great Neck investment banker Jonathan Gilbert, who partners in fitness-nutrition enterprise Decision Nutrition with his wife, Keren Gilbert, among other ventures – and the University of Miami stand ready with a planned five-year, $16 million study of cannabinoid-based methods…


Tackling concussions with cannabis

By GREGORY ZELLER // A research effort stretching from Florida to Long Island to Canada’s Alberta province will determine if compounds derived from marijuana can be effective treatments for concussions. Calgary-based R&D firm Scythian Biosciences has agreed to fund a University of Miami study, to be conducted by the university’s The Miami Project to Cure Paralysis and Miller School of Medicine, exploring cannabinoid-based methods of reducing post-concussion brain cell inflammation, which causes headaches and other neurological complications….